--- title: Postoperative Pain Control Results Using Periarticular Versus Intra-capsular Injection of Bupivacaine Liposome Injectable Suspension in Total Knee Arthroplasty nct_id: NCT02166632 overall_status: COMPLETED phase: NA sponsor: Broward Health study_type: INTERVENTIONAL primary_condition: Osteoarthritis, Knee countries: United States canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02166632.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02166632" ct_last_update_post_date: 2016-02-10 last_seen_at: "2026-05-12T07:25:00.714Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Postoperative Pain Control Results Using Periarticular Versus Intra-capsular Injection of Bupivacaine Liposome Injectable Suspension in Total Knee Arthroplasty **Official Title:** Prospective, Randomized Comparison of Postoperative Pain Control Results of Peri-articular Local Injection and Intra-capsular Injectinon of Bupivacaine Liposome Injectable Suspension After Total Knee Arthroplasty **NCT ID:** [NCT02166632](https://clinicaltrials.gov/study/NCT02166632) ## Key Facts - **Status:** COMPLETED - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 50 - **Lead Sponsor:** Broward Health - **Conditions:** Osteoarthritis, Knee - **Start Date:** 2014-04 - **Completion Date:** 2016-02 - **CT.gov Last Update:** 2016-02-10 ## Brief Summary The purpose of this study is to determine quantitative and qualitative differences in post-operative pain relief for patients undergoing primary total knee arthroplasty (TKA) who receive administration of a newly approved, long acting local anesthetic branded as ExparelTM (bupivacaine liposome injectable suspension) introduced by one of two different administration methods. Group 1 would receive a predetermined and standardized dose of ExparelTM introduced directly into the joint capsule at the conclusion of the surgery, effectively bathing the joint in anesthetic solution. Group 2 would receive the same predetermined and standardized dose of ExparelTM as a local infiltration anesthetic (LIA) by injecting it into the periarticular tissues in nine (9) standard sites at the conclusion of the surgery. ## Detailed Description This study is being done to determine if a difference exists between two methods of intraoperative (during surgery) administration of a long-acting local anesthetic (pain relief). Local pain relief medications are accepted as standard of care as a part of a comprehensive plan for pain relief following a total knee replacement (arthroplasty) (TKA). We expect that the addition of ExparelTM to the usual post-surgery pain control medicines and procedures will result in less need for additional pain medication. It is possible that local injection into the tissue around the total knee replacement joint (periarticular tissues) may provide more effective pain relief than injection directly into the joint (intracapsular) itself, or vice versa. It is also possible that pain relief with either method is approximately equivalent. On the day of surgery, each patient will undergo total knee arthroplasty and cared for utilizing the standard protocol for all patients that undergo total knee arthroplasty at Broward Health Medical Center. Patients in Group 1 will receive the same amount of ExparelTM injected intracapsularly. Those in is Group 2 will receive a standardized medication regimen including ExparelTM by local infiltration into the periarticular tissues at the conclusion of their TKA procedure. Study participants will undergo injection in this manner until the conclusion of the study. All subjects will be provided the same methods of postoperative pain control following their TKA surgery as those patients not enrolled in the study. ## Eligibility - **Minimum age:** 18 Years - **Maximum age:** 90 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Patients must be over the age of 18 * Patients must have a preoperative diagnosis of osteoarthritis of the knee requiring total knee arthroplasty Exclusion Criteria: * Allergy to ExparelTM or certain other local anesthetic agents * Pregnant females or females who think they may become pregnant * Markedly abnormal kidney function or renal disease * History of substance abuse * History of chronic pain requiring medication * Had a previous total knee arthroplasty on the same knee which is being replaced (revision total knee arthroplasty) * Had a previous partial knee arthroplasty, such as a unicompartmental knee arthroplasty on the same knee (also a revision total knee arthroplasty) ``` ## Arms - **Intracapsular Injection** (EXPERIMENTAL) — Patients in the experimental group will undergo direct injection of ExparelTM into the knee joint; once the total knee replacement (arthroplasty) has been completed, patients will receive a given amount of ExparelTM administered during surgery into the joint where the knee replacement (arthroplasty) (TKA) was performed. - **Periarticular Injection** (ACTIVE_COMPARATOR) — Patients in this group will undergo local injection of ExparelTM to help to reduce post-surgery pain. Once the total knee replacement (arthroplasty) has been completed, patients in this group will receive a given amount of ExparelTM administered during surgery into the soft tissues around the bone where the knee replacement (arthroplasty) (TKA) was performed. ## Interventions - **Intracapsular Injection** (PROCEDURE) — The amount of bupivacaine liposome (ExparelTM) will be injected directly into the joint capsule (intracapsular injection), effectively "bathing" the joint in the medication. - **Periarticular Injection** (PROCEDURE) — The amount of bupivacaine liposome (ExparelTM) will be injected periarticulary, via 9 standard periarticular tissue sites around the joint ## Primary Outcomes - **Change in Visual Analog Scale for Pain** _(time frame: 8 weeks pre-surgery (Baseline/Day 0) and every day for 1 week, post-surgery (Day 1, 2, 3, 4, 5, 6, 7))_ — Pre-Surgical visual analog scale for pain will be administered up to 2 months pre-surgery. Post-Surgical visual analog scales will be administered as a "pain journal" in which patients will record their level of pain twice a day, once in the morning, and once in the evening for 1 week. ## Secondary Outcomes - **Change in Oxford Knee Score** _(time frame: 8 weeks pre-surgery (baseline) and 4 weeks post surgery (Day 28))_ ## Locations (1) - Broward Health Sports Medicine, Fort Lauderdale, Florida, United States ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.broward health sports medicine|fort lauderdale|florida|united states` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT02166632.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT02166632* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*